{"id":61,"date":"2025-08-19T03:07:59","date_gmt":"2025-08-19T03:07:59","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=61"},"modified":"2025-08-31T03:39:10","modified_gmt":"2025-08-31T03:39:10","slug":"china-bd-deal-remegen-and-santen-enters-a-1-3-billion-rmb-license-on-anti-vegf-fgf-fusion-protein-rc28-e","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/61.html","title":{"rendered":"[China BD Deal] RemeGen and Santen enters a 1.3 billion RMB license on Anti-VEGF\/FGF Fusion Protein RC28-E"},"content":{"rendered":"\n<p>Announced Date: 2025-08-19 (August 19, 2025)<\/p>\n\n\n\n<p>Asset Name: RC28-E Intravitreal Injection<\/p>\n\n\n\n<p>Licensor: RemeGen (RemeGen Co., Ltd., China)<\/p>\n\n\n\n<p>Licensee (Buyer):  Santen\uff08Santen Pharmaceutical Co., Ltd\uff0cJapan; Santen Pharmaceutical (China) Co. Ltd.\uff09<\/p>\n\n\n\n<p>Asset Target: Vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF).&nbsp;<\/p>\n\n\n\n<p>Asset Modality: Bi-specific fusion protein drug <\/p>\n\n\n\n<p>Current Stage: Phase III, China<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>RemeGen has granted Santen a paid license for its proprietary RC28-E intravitreal injection. Santen has obtained exclusive rights to develop, manufacture, and commercialize RC28-E within the following business territories: Mainland China, Taiwan, Hong Kong, Macau, South Korea, Thailand, Vietnam, Singapore, the Philippines, Indonesia, and Malaysia.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of&nbsp;RMB 250 million;<\/p>\n\n\n\n<p> Development and regulatory milestone payments up to &nbsp;RMB 520 million;<\/p>\n\n\n\n<p>Sales milestone payments of up to RMB 525 million;<\/p>\n\n\n\n<p>Additional royalties based on net sales in the licensed territories.<\/p>\n\n\n\n<p>Total RMB 1.295 billion plus<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p>Santen Announces New Licensing Agreement with RemeGen for RC28-E Intravitreal Injection, an Anti-VEGF\/FGF Dual-Target Fusion Protein<\/p>\n\n\n\n<p><a href=\"https:\/\/www.santen.com\/en\/news\/2025\/2025_1\/20250819\">https:\/\/www.santen.com\/en\/news\/2025\/2025_1\/20250819<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-08-19 (August 19, 2025) Asset Name: RC28-E Intravitreal Injection Licensor: RemeGen (RemeGen Co., Ltd., &hellip; <a title=\"[China BD Deal] RemeGen and Santen enters a 1.3 billion RMB license on Anti-VEGF\/FGF Fusion Protein RC28-E\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/61.html\"><span class=\"screen-reader-text\">[China BD Deal] RemeGen and Santen enters a 1.3 billion RMB license on Anti-VEGF\/FGF Fusion Protein RC28-E<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-61","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/61","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=61"}],"version-history":[{"count":4,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/61\/revisions"}],"predecessor-version":[{"id":95,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/61\/revisions\/95"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=61"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=61"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=61"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}